Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Authors:
Guiomar Mendieta Badimon 1; Paul M. Ridker 2; Pernille Auerbach 3; Barry A. Borlaug 4; Maja Cikes 5; Anique Ducharme 6; Marat Fudim 7; Anders Hvelplund 3; Carolyn S.P. Lam 8; Marie Mide Michelsen 3; Adriaan A. Voors 9; Mark C Petrie 10